Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HR091506 tablets versus febuxostat in gout with hyperuricemia
CTR20241690Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HR091506 in gout, hyperuricemia, sponsored by Hengrui Therapeutics. Started May 2024; status: completed.
02
Drugs
HR091506
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20241690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241690.